First Tracks Biotherapeutics, Inc.NASDAQ: TRAX

First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026

· Issued by First Tracks Biotherapeutics, Inc. via GlobeNewswire

Summary by 6ix AI

First Tracks Biotherapeutics, a clinical-stage biotech developing antibody therapies for autoimmune and inflammatory diseases, will host an investor call and live webcast on Monday, October 12, 2026, at 8:30am ET/5:30am PT to review top-line (first headline) data from Cohort 1 of its global Phase 1b (early-stage) trial of ANB033 in celiac disease.

Key details

  • ANB033 is an investigational drug that blocks a target called CD122.
  • Cohort 1 is a gluten-challenge study assessing prevention of damage to the gut lining (mucosal damage).
  • The data will be provided in a morning press release and presented during the webcast, which will be available on the First Tracks website.
  • A replay of the webcast will be available for at least 30 days after the event.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/first-tracks-biotherapeutics-to-announce-top-line-data-from-cohort-1-of-phase-1b-trial-of-anb033-a-cd122-antagonist-in-celiac-disease-on-oct-12-2026

SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT.

A live webcast of the call will be available on the First Tracks website at: https://ir.firsttracksbio.com/news-events/events. The data will be provided in a morning press release and presented during the webcast. A replay of the webcast will be available for at least 30 days following the event.

About First Tracks Biotherapeutics

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. To learn more, visit www.FirstTracksBio.com or follow us on LinkedIn.

Investor Contact: Nick MontemaranoVice President, Investor Relations858.732.0178 investors@firsttracksbio.com

Primary Logo

Source: First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics, Inc. on 6ix

In the deck

Earlier from First Tracks Biotherapeutics

Later from First Tracks Biotherapeutics

All First Tracks Biotherapeutics news releases